---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-133363"
form_type: "8-K"
ticker: "IBRX"
cik: "0001326110"
company_name: "ImmunityBio, Inc."
filed_at: "2026-03-31T23:59:59+00:00"
generated_at: "2026-05-15T08:07:08.140262+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ImmunityBio secures $75M non-dilutive RIPA financing; $25M note conversion reduces debt

## Summary
- Additional $75M under Revenue Interest Purchase Agreement (RIPA) with Oberland Capital; total committed capital $375M.
- Royalty payback rate increased to tiered 5.625%-12.5% of net sales; cap at 195% of cumulative payments.
- Proceeds to support global expansion, pipeline advancement, and general corporate purposes.
- Nant Capital converted $25M of convertible note into 4,606,596 shares; note outstanding now $480M.
- Recent ANKTIVA approvals in US, UK, EU, Saudi Arabia, Macau; covering ~34 countries.

## SEC filing metadata
- accession: 0001193125-26-133363
- form_type: 8-K
- ticker: IBRX
- cik: 0001326110
- company_name: ImmunityBio, Inc.
- filed_at: 2026-03-31T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.03, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326110/000119312526133363/0001193125-26-133363-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326110/000119312526133363/d139829d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-133363
- JSON: https://secwatch.observer/filing/0001193125-26-133363.json
- Plain text: https://secwatch.observer/filing/0001193125-26-133363.txt

## Source-grounded claims
- claim_id: 6d0e45b4f29132fcf4dcbd0413d59cf1995535b6
  claim: ImmunityBio, Inc. incurred debt of $75.0 million with Infinity SA LLC, as collateral agent and administrative agent for the Purchasers at tiered range of 5.625% to 12.50%.
  evidence_excerpt: (the “Company”) entered into a Second Amendment to Revenue Interest Purchase Agreement (the “Amendment”) by and among the Company, the guarantors party thereto, the purchasers party thereto (the “Purchasers”) and Infinity SA LLC, as collateral agent and administrative agent for the Purchasers (the “Agent”), which amends that certain Revenue Interest Purchase Agreement dated as of December 29, 2023, by and among the Company, the Purchasers and the Agent (as amended, modified and supplemented prior to the date of the Amendment, the “RIPA”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326110/000119312526133363/0001193125-26-133363-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.